More interestingly, the present study showed LSD1 inhibitor demonstrated its potential in preventing from tumour relapse after the withdrawal of anti‐PD1 therapy in a tumour‐bearing mice model that exhibited sensitivity to anti‐PD1 therapy. Here, KDM1A is linked to neoplasm.